Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Squamous Cell Carcinoma of Head and Neck 19Breast Neoplasms 18Lung Neoplasms 17Colorectal Neoplasms 15Neoplasms 12Neoplasm Metastasis 12Head and Neck Neoplasms 12Ovarian Neoplasms 11Small Cell Lung Carcinoma 9Recurrence 9Sarcoma 8Pancreatic Neoplasms 8Prostatic Neoplasms 7Advanced Solid Tumors 7Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 6Melanoma 6Lymphoma, Large B-Cell, Diffuse 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5Carcinoma, Renal Cell 5Carcinoma, Hepatocellular 5Biliary Tract Neoplasms 5Mesothelioma, Malignant 4Lymphoma, Follicular 4Lymphoma 4Fallopian Tube Neoplasms 4Esophageal Neoplasms 4Cholangiocarcinoma 4

Interventions

Gemcitabine 27Fluorouracil 25Oxaliplatin 21Cisplatin 19Leucovorin 17Bevacizumab 15130-nm albumin-bound paclitaxel 13Docetaxel 12Capecitabine 12Albumin-Bound Paclitaxel 12Paclitaxel 11Irinotecan 10Carboplatin 9pembrolizumab 7Radiotherapy 6Pemetrexed 6Nivolumab 6Erlotinib Hydrochloride 6Cyclophosphamide 6Trastuzumab 5Ramucirumab 5Ipilimumab 4Everolimus 4Crizotinib 4Cetuximab 4vandetanib 3trastuzumab deruxtecan 3sargramostim 3folfirinox 3Sorafenib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma × durvalumab × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03777813 2025-11-18

ARION

UNICANCER

Phase 2 Completed
112 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Squamous Cell, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡